nach oben

Erschienen in:

2023 | OriginalPaper | Buchkapitel

20. Persönlichkeitsstörungen

verfasst von : Prof. Dr. med. Klaus Schmeck, Prof. Dr. med. Marcel Romanos

Erschienen in: Neuro-/Psychopharmaka im Kindes- und Jugendalter

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zur Behandlung der Kernsymptome von Persönlichkeitsstörungen sind spezifische Psychotherapieverfahren das Mittel der Wahl. Die Evidenz für eine psychopharmakologische Behandlung von Persönlichkeitsstörungen ist zwar gering, jedoch ist deren pharmakologische Behandlung weit verbreitet. In Einzelfällen können Neuro‑/Psychopharmaka sinnvoll als Komplementärtherapie zur Behandlung spezifischer Symptomdimensionen eingesetzt werden. Zum Einsatz kommen meist Stimmungsstabilisatoren und Antipsychotika der zweiten und dritten Generation. Der Einsatz von Antidepressiva ist vor allem bei Komorbiditäten aus dem internalisierenden Spektrum sinnvoll. Behandlungsansätze mit Omega-3-Fettsäuren, Opiat-Antagonisten oder Oxytocin erweitern das Behandlungsspektrum, jedoch kann auf Basis der dürftigen Datenlage derzeit keine Behandlungsempfehlung ausgesprochen werden.

Amminger GP, Chanen AM, Ohmann S et al. (2013) Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can J Psychiatry 58:402–408PubMedCrossRef

DGPPN e. V. (2022) für die Leitliniengruppe: S3-Leitlinie Borderline-Persönlichkeitsstörung. Version 1.0 vom 14.11.2022 verfügbar unter https://www.awmf.org/leitlinien

Bateman AW, Fonagy P (2000) Effectiveness of psychotherapeutic treatment of personality disorder. Brit J Psychiatry 177:138–143CrossRef

Beck E, Bo S, Jørgensen MS et al. (2020) Mentalization-based treatment in groups for adolescents with borderline personality disorder: a randomized controlled trial. J Child Psychol Psychiatry Allied Discip 61:594–604CrossRef

Bellino S, Rinaldi C, Bozzatello P, Bogetto F (2011) Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose. Curr Med Chem 18:3322–3329PubMedCrossRef

Bellino S, Bozzatello P, Rocca G, Bogetto F (2014) Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 28:125–32PubMedCrossRef

Bertsch K, Gamer M, Schmidt B et al. (2013) Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry 170:1169–1177PubMedCrossRef

Black DW, Zanarini MC, Romine A et al. (2014) Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 171:1174–1182. https://doi.org/10.1176/appi.ajp.2014.13101348CrossRefPubMed

Bogenschutz MP, Nurnberg GH (2004) Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65:104–109PubMedCrossRef

Bohus MJ, Landwehrmeyer GB, Stiglmayr CE et al. (1999) Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 60:598–603. https://doi.org/10.4088/jcp.v60n0906CrossRefPubMed

Bozzatello P, Rocca P, De Rosa ML, Bellino S (2020) Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother 21:47–61. https://doi.org/10.1080/14656566.2019.1686482CrossRefPubMed

Bozzatello P, Rocca P, Bellino S (2018) Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study. Clin Drug Investig 38:367–372. https://doi.org/10.1007/s40261-017-0617-xCrossRefPubMed

Bridler R, Häberle A, Müller ST et al. (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25:763–772. https://doi.org/10.1016/j.euroneuro.2015.03.017CrossRefPubMed

Chanen AM, Jackson HJ, McCutcheon L et al. (2008) Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: a randomised controlled trial. Br J Psychiatry 193:477–484PubMedCrossRef

Chanen AM, Betts JK, Jackson H et al. (2022) A comparison of adolescent versus young adult outpatients with first-presentation Borderline Personality Disorder: findings from the MOBY randomized controlled trial. Can J Psychiatry 67:26–38PubMedCrossRef

Choi-Kain LW, Sharp C (eds)(2021) Handbook of good psychiatric management for adolescents with borderline personality disorder. American Psychiatric Association Publishing, WashingtonCrossRef

ClinicalTrials.gov (2020) Ketamine in borderline personality disorder – tabular view. https://clinicaltrials.gov/ct2/show/record/NCT03395314. Zugegriffen: 7. Apr. 2020

Correll CU, Manu P, Olshanskiy V et al. (2009) Cardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescents. JAMA 302:1765–1773PubMedPubMedCentralCrossRef

Correll CU, Cortese S, Croatto G et al. (2021) Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry 20:244–275. https://doi.org/10.1002/wps.20881CrossRefPubMedPubMedCentral

Cowdry R, Gardner DL (1988) Pharmacotherapy in borderline personality disorder. Arch Gen Psychiatry 45:111–119PubMedCrossRef

Crawford MJ, Sanatinia R, Barrett B et al. (2018) Lamotrigine for people with borderline personality disorder: a RCT. Health Technol Assess 22:1–68. https://doi.org/10.3310/hta22170CrossRefPubMedPubMedCentral

de la Fuente JM, Lotstra F (1994) A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 4:479–486PubMedCrossRef

Domes G, Ower N, von Dawans B et al. (2019) Effects of intranasal oxytocin administration on empathy and approach motivation in women with borderline personality disorder: a randomized controlled trial. Transl Psychiatry 9:328. https://doi.org/10.1038/s41398-019-0658-4CrossRefPubMedPubMedCentral

Enning F, Schmahl C (2021) Behandlung dissoziativer Symptome mit Nalmefen bei Patienten mit Borderline-Persönlichkeitsstörung und komplexer posttraumatischer Belastungsstörung. Nervenarzt. https://doi.org/10.1007/s00115-021-01239-1CrossRefPubMedPubMedCentral

Euler S, Dammann G, Endtner K et al. (2018) Borderline-Persönlichkeitsstörung: Behandlungsempfehlungen der Schweizer Gesellschaft für Psychiatrie und Psychotherapie (SGPP). Swiss Arch Neurol Psychiatr Psychother 169:135–143

Fleischhaker C (2011) DBT-A-Manual: Dialektisch-behaviorale Therapie für Jugendliche. Springer, Heidelberg, New YorkCrossRef

Foelsch P, Schlüter-Müller S, Odom A, Arena H, Borzutzky A, Schmeck K (2013) Behandlung von Jugendlichen mit Identitätsstörungen (AIT) – Ein integratives Therapiekonzept für Persönlichkeitsstörungen. Springer, Heidelberg, New YorkCrossRef

Fonagy P, Speranza M, Luyten P, et al. (2015) ESCAP Expert Article: Borderline personality disorder in adolescence: An expert research review with implications for clinical practice. Eur Child Adolesc Psychiatry 24:1307–1320PubMedCrossRef

Gallagher AT, Byrne F, Murray IT et al. (2017) Lipids and polyunsaturated fatty acid levels in deliberate self-harm: a 10-year follow-up study. Ir J Psychol Med 34:117–126. https://doi.org/10.1017/ipm.2016.34CrossRefPubMed

Gartlehner G, Crotty K, Kennedy S et al. (2021) Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis. CNS drugs, 35:1053–1067. https://doi.org/10.1007/s40263-021-00855-4

Gerlach M, Warnke A (2010) Therapy with mood stabilizers in child and adolescent psychiatry. Psychopharmakotherapie 17:183–187

Hallahan B, Hibbeln JR, Davis JM, Garland MR (2007) Omega-3 fatty acid supplementation in patients with recurrent self-harm: Single-centre double-blind randomised controlled trial. Brit J Psychiat 190:118–122PubMedCrossRef

Herpertz SC, Zanarini M, Schulz CS et al. (2007) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 8:212–244PubMedCrossRef

Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB (2005) Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162:621–624PubMedCrossRef

Jørgensen MS (2021) Results of the Cochrane review on pharmacological interventions for people with borderline personality disorder. Vortrag auf dem Kongress der International Society for the Study of Personality Disorders (ISSPD), Oslo, 12. Okt. 2021

Kapfhammer HP (2003) Pharmakotherapie bei Persönlichkeitsstörungen. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme, Stuttgart New York, S 152–164

Kavoussi RJ, Coccaro EF (1998) Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 59:676–680PubMedCrossRef

Khalifa NR, Gibbon S, Völlm BA, Cheung NHY, McCarthy L (2020) Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007667.pub3CrossRefPubMedPubMedCentral

Knappich M, Hörz-Sagstetter S, Schwerthöffer D, Leucht S, Rentrop M (2014) Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices. Int Clin Psychopharmacol 29:224–228PubMedPubMedCentralCrossRef

Koch J, Modesitt T, Palmer M et al. (2016) Review of pharmacologic treatment in cluster A personality disorders. Ment Health Clin 6:75–81. https://doi.org/10.9740/mhc.2016.03.75CrossRefPubMedPubMedCentral

Kulkarni J, Thomas N, Hudaib et al. (2018) Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in Borderline Personality Disorder: An exploratory, randomised, double-blind, placebo-controlled trial. CNS Drugs 32:179–187PubMedCrossRef

Lampe L, Malhi GS (2018) Avoidant personality disorder: current insights. Psychol Res Behav Manag 11:55–66PubMedPubMedCentralCrossRef

Leiberich P, Nickel MK, Tritt K, Pedrosa GF (2008) Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up. J Psychopharmacol 22:805–808PubMedCrossRef

Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM (2010) Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Brit J Psychiat 196:4–12PubMedCrossRef

Lieb K, Stoffers J, Dulz B (2014) Pharmakologische Behandlung von Borderline-Persönlichkeitsstörungen. Empfehlung der Gesellschaft zur Erforschung und Therapie von Persönlichkeitsstörungen e. V. Nervenheilkunde 33:720–722CrossRef

Lieb K, Stoffers-Winterling J, Leitliniengruppe (2020) Die neuen S3-Leitlinien: Borderline Persönlichkeitsstörung. Psychother Forum 24:87–88. https://doi.org/10.1007/s00729-020-00162-1CrossRef

Links PS, Steiner M, Boiago I (1990) Lithium therapy for borderline patients: preliminary findings. J Pers Dis 4:173–181CrossRef

Loew TH, Nickel MK, Muehlbacher M et al. (2006) Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 26:61–66. https://doi.org/10.1097/01.jcp.0000195113.61291.48CrossRefPubMed

Loew TH, Nickel MK (2008) Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up. J Clin Psychopharmacol 28:355–357. https://doi.org/10.1097/JCP.0b013e318173a8CrossRefPubMed

Loose C (2015) Die Schematherapie bei adoleszenten Patienten mit Borderline-Störung. Persönlichkeitsstörungen Theor Ther 19:44–54

Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000) A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649–654PubMedCrossRef

Mazza M, Marano G, Janiri L (2016) An update on pharmacotherapy for personality disorders. Expert Opin Pharmacother 17:1977–1979. https://doi.org/10.1080/14656566.2016.1220542CrossRefPubMed

National Health and Medical Research Council (2012) Clinical practice guideline for the management of borderline personality disorder. National Health and Medical Research Council, Melbourne

National Health and Medical Research Council (2013) Caring for People with Borderline Personality Disorder: A reference guide for health professionals. National Health and Medical Research Council, Melbourne

NICE (National Institute for Health and Clinical Excellence) (2009) Borderline personality disorder – Treatment and management. NICE clinical guideline 78 (guidance.nice.org.uk/cg78. www.nice.org.uk/CG78)

Nickel MK, Loew TH (2008) Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry 23:115–117PubMedCrossRef

Nickel MK, Nickel C, Mitterlehner FO et al. (2004) Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 65:1515–1519. https://doi.org/10.4088/jcp.v65n1112CrossRefPubMed

Nickel MK, Nickel C, Kaplan P et al. (2005) Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 57:495–499PubMedCrossRef

Nickel MK, Muehlbacher M, Nickel C et al. (2006) Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind placebo-controlled study. Am J Psychiatry 163:833–838PubMedCrossRef

Nickel MK, Loew TH, Pedrosa GF (2007) Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology 191:1023–1026PubMedCrossRef

Paris J (2002) Chronic suicidality among patients with borderline personality disorder. Psychiatr Serv 53:738–742PubMedCrossRef

Pascual JC, Soler J, Puigdemont D et al. (2008) Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 69:603–608PubMedCrossRef

Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR (2015) The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry 76:e512–e518PubMedCrossRef

Quante A, Röpke S, Merkl A, Anghelescu I, Lammers CH (2008) Pharmakologische Behandlung von und bei Persönlichkeitsstörungen. Fortschr Neurol Psychiat 76:139–148PubMedCrossRef

Rathus JH, Miller AL (2002) Dialectical behavior therapy adapted for suicidal adolescents. Suicide & life-threatening behavior 32:146–157. https://doi.org/10.1521/suli.32.2.146.24399

Riffer R, Farkas M, Streibl L, Kaiser E, Sprung M (2019) Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract 23:178–188. https://doi.org/10.1080/13651501.2019.1576904CrossRefPubMed

Rossouw TI, Fonagy P (2012) Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 51:1304–1313PubMedCrossRef

Schmahl C, Kleindienst N, Limberger M et al. (2012) Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol 27:61–68PubMedCrossRef

Schmeck K, Schlüter-Müller S, Resch F (2011) Persönlichkeitsstörungen. In: Fegert JM, Eggers C, Resch F (Hrsg) Lehrbuch der Kinder- und Jugendpsychiatrie, 2. Aufl. Springer, Heidelberg New York, S 635–652

Schmeck K, Weise S, Schlüter-Müller S et al. (2022) Effectiveness of adolescent identity treatment (AIT) vs. DBT-A for the treatment of adolescent borderline personality disorder. Pers Disord Theory Res Treat. https://doi.org/10.1037/per0000572CrossRef

Schmeck K, Kaess M (2022) Persönlichkeitsstörungen. In: Fegert JM, Eggers C, Resch F (Hrsg) Lehrbuch der Kinder- und Jugendpsychiatrie, 3. Aufl. Springer, Heidelberg New York

Schneider I, Boll S, Volman I et al. (2020) Oxytocin normalizes approach-avoidance behavior in women with borderline personality disorder. Front Psychiatry 11:120. https://doi.org/10.3389/fpsyt.2020.00120CrossRefPubMedPubMedCentral

Schuppert HM, Timmerman ME, Bloo J et al. (2012) Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. J Am Acad Child Adol Psych 51:1314–1321CrossRef

Sharp C, Fonagy P (2015) Practitioner Review: Borderline personality disorder in adolescence - recent conceptualization, intervention, and implications for clinical practice. J Child Psychol Psychiatry 56:1266–1288PubMedCrossRef

Simonsen S, Bateman A, Bohus M et al. (2019) European guidelines for personality disorders: past, present and future. Borderline personality disorder and emotion dysregulation, 6:9. https://doi.org/10.1186/s40479-019-0106-3

Simpson EB, Yen S, Costello E et al. (2004) Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65:379–385PubMedCrossRef

Soler J, Pascual JC, Campins J et al. (2005) Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162:1221–1224PubMedCrossRef

Soloff PH, Nathan RS, George A et al. (1993) Progress in pharmacotherapy of borderline disorders: a double blind study of amitriptyline, haloperidol and placebo. Arch Gen Psychiatry 43:691–697CrossRef

Stoffers JM, Völlm BA, Rücker G et al. (2012) Psychological therapies for people with borderline personality disorder. Cochrane Db Syst Rev 8:CD5652. https://doi.org/10.1002/14651858.CD005652.pub2CrossRef

Stoffers J, Völlm BA, Rücker G et al. (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 6:CD5653. https://doi.org/10.1002/14651858.CD005653.pub2CrossRef

Stoffers-Winterling J, Storebø OJ, Lieb K (2020) Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep 22:37. https://doi.org/10.1007/s11920-020-01164-1CrossRefPubMedPubMedCentral

Stoffers-Winterling J, Storebø OJ, Simonsen E, Lieb K (2021) Evidence in context: current clinical guidelines and the new Cochrane review. Vortrag auf dem Kongress der International Society for the Study of Personality Disorders (ISSPD), Oslo, 12. Okt. 2021

Starcevic V, Janca A (2018) Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism. Curr Opin Psychiatry 31:69–73PubMedCrossRef

Taubner S, Volkert J (2016) Mentalisierungsbasierte Therapie für Adoleszente (MBT-A). Vandenhoeck & Rupprecht, GöttingenCrossRef

Timäus C, Meiser M, Wiltfang J, Bandelow B, Wedekind D (2021) Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients. Hum Psychopharmacol. https://doi.org/10.1002/hup.2800CrossRefPubMed

Triebwasser J, Siever LJ (2007) Pharmacotherapy of personality disorders. J Ment Health 16:5–50CrossRef

Tritt K, Nickel C, Lahmann C et al. (2005) Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 19:287–291PubMedCrossRef

Vanicek T, Unterholzner J, Lanzenberger R et al. (2022) Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World J Biol Psychiatry. https://doi.org/10.1080/15622975.2022.2031287CrossRefPubMed

WHO (2019) ICD-11. https://icd.who.int/browse11/l-m/en. Zugegriffen: 12. Dez. 2019

Wollmer MA, Neumann I, Jung S et al. (2022) Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: A randomized controlled trial. J Psychopharmacol 36:159–169. https://doi.org/10.1177/02698811211069108

Zanarini MC, Frankenburg FR (2001) Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62:849–854PubMedCrossRef

Zanarini MC, Frankenburg FR (2003) Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiat 160:167–169PubMedCrossRef

Zanarini MC, Frankenburg FR, Parachini EA (2004) A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 7:903–907CrossRef

Zanarini MC, Schulz SC, Detke HC et al. (2011). A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 72:1353–1362. https://doi.org/10.4088/JCP.08m04138yel

Titel: Persönlichkeitsstörungen
verfasst von: Prof. Dr. med. Klaus Schmeck
Prof. Dr. med. Marcel Romanos
Verlag: Springer Berlin Heidelberg
Buch: Neuro-/Psychopharmaka im Kindes- und Jugendalter
Print ISBN: 978-3-662-65266-4

Electronic ISBN: 978-3-662-65267-1

Copyright-Jahr: 2023
DOI: https://doi.org/10.1007/978-3-662-65267-1_20

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).